<DOC>
	<DOCNO>NCT03029481</DOCNO>
	<brief_summary>Despite improvement outcomes patient localize Ewing sarcoma , patient relapse metastatic Ewing sarcoma continue poor outcome current chemotherapy option . A large body preclinical data support role IGF-1R inhibition treatment Ewing sarcoma . More recently , clinical trial IGF-1R monoclonal antibody demonstrate single- agent activity patient relapse Ewing sarcoma . Ganitumab ( AMG 479 ) fully human monoclonal antibody direct IGF-1R . We propose single-agent expanded access IND provide patient opportunity benefit treatment develop progressive disease multiple line prior therapy .</brief_summary>
	<brief_title>Single Patient Expanded Access Ganitumab Metastatic Ewing Sarcoma</brief_title>
	<detailed_description>Despite improvement outcomes patient localize Ewing sarcoma , patient relapse metastatic Ewing sarcoma continue poor outcome current chemotherapy option . A large body preclinical data support role IGF-1R inhibition treatment Ewing sarcoma . More recently , clinical trial IGF-1R monoclonal antibody demonstrate single- agent activity patient relapse Ewing sarcoma . Ganitumab ( AMG 479 ) fully human monoclonal antibody direct IGF-1R . We propose single-agent expanded access IND provide patient opportunity benefit treatment develop progressive disease multiple line prior therapy .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis : Confirmed translocationpositive Ewing sarcoma Organ Function Requirements : Serum creatinine &lt; 1.4 Adequate liver function Total bilitubin &lt; 1.5x upper limit normal age SGPT ( ALT ) &lt; 5x upper limit normal age Adequate cardiac function &gt; 50 % echocardiogram Bone Marrow Absolute neutrophil count &gt; 750 Platelet count &gt; 75 Female patient childbearing potential eligible unless negative pregnancy test result obtain . Lactating female eligible unless agree breastfeed infant duration protocol therapy . Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration protocol therapy . Patients know preexist diabetes mellitus exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>48 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>